TrialPloS one2014

Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.

Yong Kyu Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.